Rasanen JE, et al. - Researchers evaluated the effectiveness, tolerability and cost-effectiveness of BF-200 ALA compared with methyl-5-aminolevulinate (MAL) in daylight photodynamic therapy (DL-PDT) for grade I-II actinic keratosis (AK). They conducted a non-sponsored, prospective randomized double-blind multicentre trial and included 69 patients with 767 grade I-II AKs located symmetrically on the face or scalp. Findings suggested a greater efficacy of BF-200 ALA MAL in DL-PDT for grade I-II AKs. Slightly better value for money was provided by BF-200 ALA than MAL. In >90% of cases, the cosmetic outcome was excellent or good with both photosensitizers.